Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to
assess the efficacy and safety profile of cabozantinib in patients with brain metastases from
metastatic renal cell carcinoma (mRCC).